Table 2.
MIC50 and MIC90 for ATI-2307 and amphotericin B are equivalent across Cryptococcus neoformans clinical isolates with differing fluconazole IC50.
| Fluconazole IC50 (µg/mL) | |||||
|---|---|---|---|---|---|
| Total (n = 69) | IC50 ≤ 2 (n = 6) | IC50 = 8 (n = 28) | IC50 = 16 (n = 26) | IC50 ≥ 32 (n = 9) | |
| ATI-2307 | |||||
| IC50 min | 0.0078 | 0.0078 | 0.0078 | 0.0078 | 0.0078 |
| IC50 max | 0.0624 | 0.0624 | 0.0156 | 0.0312 | 0.0156 |
| MIC50* | 0.0156 | 0.0156 | 0.0156 | 0.0078 | 0.0156 |
| MIC90* | 0.0156 | 0.0624 | 0.0156 | 0.0156 | 0.0156 |
| Amphotericin B | |||||
| IC90 min | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| IC90 max | 2.0 | 1.0 | 1.0 | 1.0 | 2.0 |
| MIC50* | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| MIC90* | 1.0 | 0.5 | 1.0 | 1.0 | 1.0 |
*MIC50 and MIC90 are the drug concentrations at which 50% or 90% of the strains tested have an IC50 or IC90 at or below the indicated drug concentration, respectively.